DE2945788C2 - - Google Patents

Info

Publication number
DE2945788C2
DE2945788C2 DE2945788A DE2945788A DE2945788C2 DE 2945788 C2 DE2945788 C2 DE 2945788C2 DE 2945788 A DE2945788 A DE 2945788A DE 2945788 A DE2945788 A DE 2945788A DE 2945788 C2 DE2945788 C2 DE 2945788C2
Authority
DE
Germany
Prior art keywords
adjuvant
antigen
immune substance
blood cells
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2945788A
Other languages
German (de)
English (en)
Other versions
DE2945788A1 (de
Inventor
John Shearer River Vale N.J. Us Wolff Iii
George Robert Sparta N.J. Us Hemsworth
Keith Edwin Waterford Conn. Us Jensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE2945788A1 publication Critical patent/DE2945788A1/de
Application granted granted Critical
Publication of DE2945788C2 publication Critical patent/DE2945788C2/de
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE19792945788 1979-10-26 1979-11-13 Arzneimittel und seine verwendung Granted DE2945788A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/088,638 US4310550A (en) 1979-10-26 1979-10-26 Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants

Publications (2)

Publication Number Publication Date
DE2945788A1 DE2945788A1 (de) 1981-05-07
DE2945788C2 true DE2945788C2 (en:Method) 1988-01-28

Family

ID=22212534

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19792945788 Granted DE2945788A1 (de) 1979-10-26 1979-11-13 Arzneimittel und seine verwendung

Country Status (7)

Country Link
US (1) US4310550A (en:Method)
JP (1) JPS5671024A (en:Method)
AU (1) AU522338B2 (en:Method)
CA (1) CA1163562A (en:Method)
DE (1) DE2945788A1 (en:Method)
NZ (1) NZ195354A (en:Method)
PT (1) PT71236A (en:Method)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3604109A1 (de) * 1985-02-10 1986-08-14 State of Israel Ministry of Agriculture, Jerusalem Impfstoff-system

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058021A3 (en) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmaceutical compositions
NL9000207A (en:Method) * 1990-01-29 1991-08-16 Duphar Int Res
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
JP2004516333A (ja) 2001-01-04 2004-06-03 ユニバーシティー オブ サスカチェワン 腸管出血性大腸菌ワクチン
EP2462948A1 (en) 2003-10-31 2012-06-13 The University Of British Columbia Bacterial virulence factors and uses thereof
NZ550152A (en) 2004-04-05 2009-04-30 Pfizer Prod Inc Microfluidized oil-in-water emulsions and vaccine compositions
US20080102067A1 (en) * 2006-10-25 2008-05-01 Cook Mark E Immunogenic composition
WO2017011918A1 (en) 2015-07-22 2017-01-26 University Of Saskatchewan Mycoplasma bovis vaccines and uses thereof
US20230218734A1 (en) 2020-04-20 2023-07-13 University Of Saskatchewan Compositions and methods for preventing, controlling and diagnosing mycobacterial infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) * 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US3872171A (en) * 1971-05-24 1975-03-18 Pfizer Polyamines as antiviral agents in animals
US4034040A (en) * 1971-05-24 1977-07-05 Pfizer Inc. Xylene-diamines as antiviral agents
US4173641A (en) * 1978-05-15 1979-11-06 Pfizer Inc. Di-O-n-alkyl glycerol derivatives as immune stimulants

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3604109A1 (de) * 1985-02-10 1986-08-14 State of Israel Ministry of Agriculture, Jerusalem Impfstoff-system

Also Published As

Publication number Publication date
NZ195354A (en) 1982-12-21
PT71236A (en) 1980-06-01
US4310550A (en) 1982-01-12
AU522338B2 (en) 1982-05-27
DE2945788A1 (de) 1981-05-07
AU6366480A (en) 1981-04-30
JPS6225646B2 (en:Method) 1987-06-04
JPS5671024A (en) 1981-06-13
CA1163562A (en) 1984-03-13

Similar Documents

Publication Publication Date Title
DE69304521T2 (de) Impfstoff Adjuvans
AT407958B (de) Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
DE3911442C2 (de) Impfstoff-Präparation
DE69937343T2 (de) Adjuvanszusammensetzung und methoden zu deren verwendung
AT408615B (de) Neue influenzavirus-impfstoffzusammensetzung
DE69015222T2 (de) Tocole als Impfstoffadjuvans.
DE69434956T2 (de) Auf einer Emusion und MPL basierte Adjuvantien für Impfstoffe
DE3886332T2 (de) Inaktivierung von Viren und Bakterien.
DE69529684T2 (de) Adjuvans für impfstoff
DE69531501T3 (de) Kombinierte meningitis-vakzine
DE3853210T2 (de) Verwendung eines viralen glykoprotein-impstoffes für intranasale immunisierung gegen eine virusinfektion.
DE69018990T2 (de) Stabile interleukine enthaltende impfstoffzusammensetzungen.
DE69934179T2 (de) Zusammensetzung enthaltend ein Antigen, ein TH-1 induzierendes Adjuvans und eine im Wasser schwer lösliche Aminosäure zur Verwendung in der Immunisierung
DE2736223A1 (de) Allergen enthaltende substanzen, verfahren zu ihrer herstellung und ihre verwendung
DE69623072T2 (de) Impfstoffzusammensetzung für Säugetiere enthaltend Squalen oder Squalan, Phospholipid und ein Tensid als Adjuvans
DE69115514T2 (de) Liposomenhaltige intranasale Impfstofformulierung
DE2945788C2 (en:Method)
DE69919984T2 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
DE68922109T2 (de) Gamma-inulin-zusammensetzungen.
DE3882781T2 (de) Impfstoff gegen Pasteurella.
DE2603321A1 (de) Emulsion auf der grundlage eines stoffwechselfaehigen pflanzlichen oels und wasser
EP0734725B1 (de) Adjuvans auf der Basis kolloidaler Eisenverbindungen
US4395394A (en) Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US6528058B1 (en) Saponin adjuvant composition
DE1924304C3 (de) Diäthylaminoäthyldextran (DEAE-D) als Adjuvans für Impfstoffe zur aktiven Immunisierung von Säugetieren

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8128 New person/name/address of the agent

Representative=s name: LEDERER, F., DIPL.-CHEM. DR., PAT.-ANW., 8000 MUEN

D2 Grant after examination
8364 No opposition during term of opposition